Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos, Cellzome Forge Kinase Drug Discovery Partnership

NEW YORK (GenomeWeb News) - Galapagos and Cellzome today said that they are collaborating in kinase drug discovery. 
 
Under the terms of the agreement, Galapagos' service division BioFocus DPI will provide its SoftFocus kinase libraries to Cellzome. BioFocus will also provide biological screening and chemistry expertise to find inhibitors of Cellzome's kinase targets, the companies said.
 
The companies will use Cellzome's proprietary proteomics technology, Kinobeads, to screen the BioFocus DPI libraries in order to identify inhibitors against inflammatory kinases. 
 
As part of the service contract, BioFocus DPI will receive an upfront payment for the library access as well as research fees. Further financial details were not disclosed.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.